Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NyxoahSTU:5YI -4.43%59 Days Inventory is 150.33 as of Mar. 2026, which is 68% below its 10-year median of 462.88. GuruFocus rates STU:5YI with a GF Score™ of 59/100 and a GF Value™ of €26.43 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Nyxoah ranks worse than 79.42% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Nyxoah's Average Total Inventories for the
three
months ended in Mar. 2026 was €4.50 Mil. Nyxoah's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €2.73 Mil.
Hence, Nyxoah's Days Inventory for the
three
months ended in Mar. 2026 was 150.33.
The historical rank and industry rank for Nyxoah's Days Inventory or its related term are showing as below:
STU:5YI'
s Days Inventory Range Over the Past 10 Years
Min: 194.88 Med: 462.88 Max: 944.37
Current: 307.86
During the past 9 years, Nyxoah's highest Days Inventory was 944.37. The lowest was 194.88. And the median was 462.88.
STU:5YI's Days Inventory is ranked worse than 79.42% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 179.47
vs STU:5YI: 307.86
Nyxoah's Days Inventory
declined
from Mar. 2025 (1,089.72) to Mar. 2026 (150.33).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Nyxoah's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.61.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nyxoah's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.71.
Nyxoah (STU:5YI) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Nyxoah's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nyxoah's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Nyxoah Days Inventory Related Terms
Nyxoah Days Inventory Historical Data
* Premium members only.
The historical data trend for Nyxoah's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:5YI vs ISRG, BDX, MDLN: Days Inventory Comparison
For the Medical Instruments & Supplies subindustry, Nyxoah's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nyxoah Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nyxoah's Days Inventory distribution charts can be found below:
* The bar in red indicates where Nyxoah's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nyxoah (STU:5YI) has a Days Inventory of 150.33 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Nyxoah and its competitors. This is 68% below median its historical median of 462.88. Over the past decade, Nyxoah's Days Inventory has ranged from 194.88 to 944.37. According to the industry distribution chart, Nyxoah ranks #625 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 79.4%.
Is Nyxoah's Days Inventory too high?
Nyxoah's current Days Inventory of 150.33 is 68% below median its 10-year median of 462.88. Over the past 10 years, this metric has ranged from a low of 194.88 to a high of 944.37. The Medical Devices & Instruments industry median Days Inventory is 179.47. Nyxoah's value of 150.33 is 16.2% below this industry median. Based on the distribution chart, Nyxoah ranks #625 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nyxoah has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nyxoah's Days Inventory compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nyxoah ranks #625 out of 787 companies for Days Inventory. This places Nyxoah in the lower half of its industry. The industry median Days Inventory is 179.47. Nyxoah's value of 150.33 is 16.2% below this benchmark. Historically, Nyxoah's own Days Inventory has ranged from 194.88 to 944.37 over the past decade. While the company's 10-year median is 462.88 vs. the industry median of 179.47, Nyxoah has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.47, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nyxoah's current Days Inventory of 150.33 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Nyxoah and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nyxoah's current Days Inventory is 150.33, which is 68% below median its own 10-year median of 462.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyxoah stock overvalued right now?
Based on GuruFocus' analysis, Nyxoah (STU:5YI) is currently considered Possible Value Trap. The stock's GF Value™ is €26.43, compared to a current price of €1.42 — trading 94.6% below its estimated fair value. The current Days Inventory is 150.33, which is 68% below median its 10-year median of 462.88 and 16.2% below the Medical Devices & Instruments industry median of 179.47. Nyxoah's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Nyxoah (STU:5YI), the current Days Inventory is 150.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nyxoah (STU:5YI) Overvalued in 2026?
Based on GuruFocus' analysis, Nyxoah stock appears to be undervalued.
The current stock price of €1.42 is trading 94.6% below its estimated GF Value™ of €26.43.
GuruFocus considers Nyxoah to be Possible Value Trap.
Key valuation signals for STU:5YI:
Days Inventory: 150.33 (68% below median its 10-year median of 462.88)
GF Value™: €26.43 vs. price of €1.42 (94.6% below fair value)
Industry Position: 16.2% below the Medical Devices & Instruments median (#625 of 787)
No single metric tells the full story. See the STU:5YI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
59GF Score
Get the complete analysis for STU:5YI
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5YI has been successfully added to your 
